 |
|
Corticotropin-Releasing Factor-like Immunoreactivity in Senile Dementia of the Alzheimer TypeReduced Cortical and Striatal Concentrations
Garth Bissette, PhD;
Gavin P. Reynolds, PhD;
Clinton D. Kilts, PhD;
Erik Widerlöv, MD, PhD;
Charles B. Nemeroff, MD, PhD
JAMA. 1985;254(21):3067-3069.
Abstract
| |
The concentration of corticotropin-releasing factor-like immunoreactivity (CRF-LI) in the human central nervous system was measured by radioimmunoassay in postmortem tissue of control patients and in those with histologically confirmed senile dementia of the Alzheimer type (SDAT). In the controls, CRF-LI was found in high concentrations in the hypothalamus and frontal cortex (Brodmann's area 10), in moderate concentrations in amygdala, substantia innominata, temporal and parietal cortex (Brodmann's areas 38 and 7), and the caudate nucleus, and in low concentrations in posterior hippocampus and nucleus accumbens. A marked reduction in the concentration of CRF-LI was observed in the frontal and temporal cortex (approximately 50%) as well as in the caudate nucleus (approximately 70%) in the SDAT group. The present findings suggest that neurons containing corticotropinreleasing factor are pathologically altered in SDAT, in addition to the previously described cholinergic and somatostatinergic neuronal degeneration.
(JAMA 1985;254:3067-3069)
Author Affiliations
From the Departments of Psychiatry (Drs Bissette, Kilts, and Nemeroff) and Pharmacology (Drs Kilts and Nemeroff) and the Center for Aging and Human Development (Dr Nemeroff), Duke University Medical Center, Durham, NC; the Medical Research Council Brain Bank, Department of Neurological Surgery and Neurology, Addenbrooke's Hospital, Cambridge, England (Dr Reynolds); and the Psychiatric Research Center, University of Uppsala (Sweden) (Dr Widerlöv). Dr Widerlöv is now with the Department of Psychiatry and Neurochemistry, University of Lund, S:t Lars Hospital, Lund, Sweden.
Footnotes
Reprint requests to Department of Psychiatry, Box 3859, Duke University Medical Center, Durham, NC 27710 (Dr Bissette).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Corticotropin-releasing hormone activates ERK1/2 MAPK in specific brain areas
Refojo et al.
Proc. Natl. Acad. Sci. USA 2005;102:6183-6188.
ABSTRACT
| FULL TEXT
Brain Region-Specific Neuroprotective Action and Signaling of Corticotropin-Releasing Hormone in Primary Neurons
Bayatti et al.
Endocrinology 2003;144:4051-4060.
ABSTRACT
| FULL TEXT
Alzheimer's Disease, Neuropeptides, Neuropeptidase, and Amyloid-{beta} Peptide Metabolism
Saito et al.
Sci Aging Knowl Environ 2003;2003:pe1-1.
ABSTRACT
| FULL TEXT
Plasma somatostatin and gastrointestinal peptides in Alzheimer's disease and vascular dementia
Foy et al.
QJM 2001;94:631-635.
ABSTRACT
| FULL TEXT
Corticotropin-Releasing Hormone-Mediated Neuroprotection against Oxidative Stress Is Associated with the Increased Release of Non-amyloidogenic Amyloid {beta} Precursor Protein and with the Suppression of Nuclear Factor-{kappa}B
Lezoualc’h et al.
Mol. Endocrinol. 2000;14:147-159.
ABSTRACT
| FULL TEXT
Neuropeptide Abnormalities in Patients With Early Alzheimer Disease
Davis et al.
Arch Gen Psychiatry 1999;56:981-987.
ABSTRACT
| FULL TEXT
The Preeminent Role of Neuropeptide Systems in the Early Pathophysiology of Alzheimer Disease: Up With Corticotropin-Releasing Factor, Down With Acetylcholine
Nemeroff
Arch Gen Psychiatry 1999;56:991-992.
FULL TEXT
Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
Gasparini et al.
FASEB J. 1998;12:17-34.
ABSTRACT
| FULL TEXT
Perspectives on the Etiology of Alzheimer's Disease
Mozar et al.
JAMA 1987;257:1503-1507.
ABSTRACT
Alzheimer's disease: clinical, neuropathologic, neuropsychologic, and brain metabolic findings
Cutler and Narang
AM J ALZHEIMERS DIS OTHER DEMEN 1986;1:16-23.
ABSTRACT
Alzheimer's Disease and Corticotropin-Releasing Factor
Swanson
JAMA 1985;254:3085-3086.
ABSTRACT
|
